보조생식기술(ART) 시장 평가 : 제품별, 기술별, 환자 유형별, 최종사용자별, 지역별 기회 및 예측(2018-2032년)

Global assisted reproductive technology (ART) market is projected to witness a CAGR of 7.56% during the forecast period 2025-2032, growing from USD 31.36 billion in 2024 to USD 56.17 billion in 2032. The market's expansion is supported by the increasing incidences of infertility in different regions across the globe, rising investments in ART, growing awareness about the availability of different reproductive solutions, and increasing government initiatives to boost awareness and accessibility of ART. The World Health Organization (WHO) estimates that approximately 17.5% of the adult population across the globe are experiencing infertility.

The market has grown significantly over the historic period and is expected to generate similar results over the forecast period due to increasing rates of infertility, rapid advancements in ART procedures, and growing awareness about different reproductive solutions. The demand for these services has been growing as more couples across the globe face fertility challenges due to lifestyle changes, delayed childbearing, and increasing prevalence of health conditions such as polycystic ovary syndrome (PCOS) and endometriosis.

Technological Advancements Drive Market Growth

Leading fertility providers across the globe are focusing on developing and introducing advanced reproductive technologies, propelling the market's expansion. Advancements in artificial intelligence, micromanipulators, time-lapse imaging systems, and advanced incubators improve the success rate and precision of intracytoplasmic sperm injections and in-vitro fertilization. Artificial intelligence (AI) powered tools assist clinicians in embryo selection, medication dosing, and streamlining clinical operations. Thus, various companies are increasingly focusing on investing in such technologies. For instance, in March 2024, Alife Health partnered with Boston IVF, LLC, to pilot the first AI tools in the United States for IVF medication optimization. The latter is implementing Alife's Stim Assist software, designed for aiding IVF clinicians in retrieving the optimal number of eggs for improved success rate of the procedure.

Rising Government Efforts Support Market Expansion

Increasing efforts by various governments to boost population growth and increase awareness and accessibility to ART services are among the major factors driving the market's growth. Most countries are considering introducing supportive policies and subsidized funding schemes in order to bolster population growth and address infertility. Additionally, national guidelines such as those in France, Germany, and Australia have provided an ethical-legal standardization for ART procedure supervision and patient safety. Moreover, rising research grants and funds for fertility science are fostering technological advancements to increase the accessibility of effective treatments.

Meanwhile, countries with declining birth rates are introducing various policies to encourage family planning, which are expected to drive the market's demand. For instance, the Tokyo Metropolitan Government plans on implementing a four-day workweek from April 2025, to improve workplace flexibility and allow parents to balance family responsibilities.

Fertility Clinics Account for Significant Share of the Market

The high popularity of fertility clinics for availing ART services can be attributed to the comprehensive range of procedures and customized treatment plans offered to the patients. Most of these clinics provide a full spectrum of procedures such as preimplantation genetic testing, sperm and egg freezing, intrauterine insemination, and in-vitro fertilization, among others. Additionally, these clinics are also equipped with advanced technological solutions and infrastructure, as well as skilled medical professionals and counsellors, ensuring higher success rates and improved patient satisfaction.

Furthermore, leading fertility clinics are investing in their expansion and focusing on providing services in previously underserved regions, further supporting the segment's growth and expansion. For instance, in February 2025, Wellnest Fertility Inc. launched the Wellnest Fertility Clinic in Utah, United States, introducing a state-of-the-art facility that delivers comprehensive fertility care with personalized treatment plans and advanced embryo monitoring technology. By incorporating continuous, time-lapse embryo monitoring, the clinic enables embryologists to observe embryo development in real time without disturbing their environment, providing invaluable insights into growth patterns and key developmental milestones. This technology enhances the precision of embryo selection, increases the likelihood of successful pregnancies, and ultimately improves patient outcomes. The expansion of such innovative services by fertility clinics worldwide is expected to boost patient confidence in fertility treatments, reduce geographical barriers to high-quality care, and create significant growth opportunities within the ART market.

Europe Holds Major Market Share

The region's dominance can be attributed to the increasing prevalence of infertility in Europe due to evolving societal norms and delayed childbearing, widespread availability of fertility services, and the presence of favorable legislation and regulations in countries such as the United Kingdom, France, and Belgium. These countries also have generous reimbursement policies, reducing out-of-pocket expenses for the patient population. Furthermore, Europe is also a hub for medical tourism in reproductive health, providing relief from higher treatment costs and restrictive laws. The easy availability and adoption of advanced technologies, including single embryo transfer and preimplantation genetic testing, are bolstering the success rate of ART, further augmenting the market's expansion. Furthermore, Europe estimates that approximately 25 million people in the European Union are affected by infertility.

Meanwhile, the market in North America is expected to witness significant growth in the coming years due to the increasing number of same-sex couples in the country, the availability and acceptance of advanced technologies, and the increasing popularity of single parenthood.

Impact of U.S. Tariffs on Global Assisted Reproductive Technology (ART) Market

These tariffs are expected to affect a significant portion of the medical device industry and influence various facets of the ART market, including international trade dynamics and production costs. Tariffs are also expected to potentially disrupt supply chains, forcing companies to relocate manufacturing processes and seek alternative suppliers, which may not be entirely feasible due to the existing regulatory and infrastructural requirements.

Moreover, manufacturers in the United States might find it challenging to compete internationally if other countries retaliate by introducing their own tariffs, resulting in market fragmentation. Thus, stakeholders in the industry will need to navigate the shift in trade dynamics and increase production costs to adapt and hold their position in the market.

Key Players Landscape and Outlook

In order to improve the treatment outcomes and aid researchers and scientists in advancing reproductive technologies, the key players of the market are focusing on new products. For instance, in July 2023, Thermo Fisher Scientific Inc. launched the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit for preimplantation genetic testing-aneuploidy (PGT-A). PGT-A is used to identify chromosomal abnormalities in embryos, allowing clinicians to select the most viable embryos for implantation and improving the success rate of the process. Such launches also provide deeper genomic insights to reproductive researchers, improving reproductive health outcomes and the success rate of pregnancies.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Instruments
      • 5.2.1.1.1. Sperm Separators
      • 5.2.1.1.2. Embryo Incubators
      • 5.2.1.1.3. Cryosystems
      • 5.2.1.1.4. Other Instruments
    • 5.2.1.2. Consumables
      • 5.2.1.2.1. Culture Dishes and Plates
      • 5.2.1.2.2. Storage Vials
      • 5.2.1.2.3. Needles
      • 5.2.1.2.4. Embryo Transfer Catheters
      • 5.2.1.2.5. Other Consumables
    • 5.2.1.3. Reagents and Media
      • 5.2.1.3.1. Embryo Culture Media
      • 5.2.1.3.2. Cryopreservation Media
      • 5.2.1.3.3. Semen Processing Media
  • 5.2.2. By Technology
    • 5.2.2.1. In-vitro Fertilization (IVF)
    • 5.2.2.2. Artificial Insemination (AI-IUI)
    • 5.2.2.3. Frozen Embryo Replacement (FER)
    • 5.2.2.4. Other Technologies
  • 5.2.3. By Patient Type
    • 5.2.3.1. Male
    • 5.2.3.2. Female
  • 5.2.4. By End-user
    • 5.2.4.1. Fertility Clinics
    • 5.2.4.2. Hospitals
    • 5.2.4.3. Surgical Centers
    • 5.2.4.4. Clinical Research Institutes
    • 5.2.4.5. Others
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product
  • 5.3.2. By Technology
  • 5.3.3. By Patient Type
  • 5.3.4. By End-user
  • 5.3.5. By Region

6. North America Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Product
    • 6.2.1.1. Instruments
      • 6.2.1.1.1. Sperm Separators
      • 6.2.1.1.2. Embryo Incubators
      • 6.2.1.1.3. Cryosystems
      • 6.2.1.1.4. Other Instruments
    • 6.2.1.2. Consumables
      • 6.2.1.2.1. Culture Dishes and Plates
      • 6.2.1.2.2. Storage Vials
      • 6.2.1.2.3. Needles
      • 6.2.1.2.4. Embryo Transfer Catheters
      • 6.2.1.2.5. Other Consumables
    • 6.2.1.3. Reagents and Media
      • 6.2.1.3.1. Embryo Culture Media
      • 6.2.1.3.2. Cryopreservation Media
      • 6.2.1.3.3. Semen Processing Media
  • 6.2.2. By Technology
    • 6.2.2.1. In-vitro Fertilization (IVF)
    • 6.2.2.2. Artificial Insemination (AI-IUI)
    • 6.2.2.3. Frozen Embryo Replacement (FER)
    • 6.2.2.4. Other Technologies
  • 6.2.3. By Patient Type
    • 6.2.3.1. Male
    • 6.2.3.2. Female
  • 6.2.4. By End-user
    • 6.2.4.1. Fertility Clinics
    • 6.2.4.2. Hospitals
    • 6.2.4.3. Surgical Centers
    • 6.2.4.4. Clinical Research Institutes
    • 6.2.4.5. Others
  • 6.2.5. By Country Share
    • 6.2.5.1. United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Product
        • 6.3.1.2.1.1. Instruments
        • 6.3.1.2.1.1.1. Sperm Separators
        • 6.3.1.2.1.1.2. Embryo Incubators
        • 6.3.1.2.1.1.3. Cryosystems
        • 6.3.1.2.1.1.4. Other Instruments
        • 6.3.1.2.1.2. Consumables
        • 6.3.1.2.1.2.1. Culture Dishes and Plates
        • 6.3.1.2.1.2.2. Storage Vials
        • 6.3.1.2.1.2.3. Needles
        • 6.3.1.2.1.2.4. Embryo Transfer Catheters
        • 6.3.1.2.1.2.5. Other Consumables
        • 6.3.1.2.1.3. Reagents and Media
        • 6.3.1.2.1.3.1. Embryo Culture Media
        • 6.3.1.2.1.3.2. Cryopreservation Media
        • 6.3.1.2.1.3.3. Semen Processing Media
      • 6.3.1.2.2. By Technology
        • 6.3.1.2.2.1. In-vitro Fertilization (IVF)
        • 6.3.1.2.2.2. Artificial Insemination (AI-IUI)
        • 6.3.1.2.2.3. Frozen Embryo Replacement (FER)
        • 6.3.1.2.2.4. Other Technologies
      • 6.3.1.2.3. By Patient Type
        • 6.3.1.2.3.1. Male
        • 6.3.1.2.3.2. Female
      • 6.3.1.2.4. By End-user
        • 6.3.1.2.4.1. Fertility Clinics
        • 6.3.1.2.4.2. Hospitals
        • 6.3.1.2.4.3. Surgical Centers
        • 6.3.1.2.4.4. Clinical Research Institutes
        • 6.3.1.2.4.5. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Import and Export Analysis

13. Value Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

• 17.1. Market Drivers
• 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework and Innovation

• 19.1. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

• 22.1. Competition Matrix of Top 5 Market Leaders
• 22.2. SWOT Analysis for Top 5 Players
• 22.3. Key Players Landscape for Top 10 Market Players
  • 22.3.1. CooperSurgical, Inc.
    • 22.3.1.1. Company Details
    • 22.3.1.2. Key Management Personnel
    • 22.3.1.3. Products and Services
    • 22.3.1.4. Financials (As Reported)
    • 22.3.1.5. Key Market Focus and Geographical Presence
    • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 22.3.2. FUJIFILM Irvine Scientific, Inc.
  • 22.3.3. Cook Group Incorporated
  • 22.3.4. Thermo Fisher Scientific Inc.
  • 22.3.5. Vitrolife Sweden AB
  • 22.3.6. Hamilton Thorne Inc.
  • 22.3.7. Ferring B.V.
  • 22.3.8. Genea Group
  • 22.3.9. Esco Lifesciences Group Ltd.
  • 22.3.10. Kitazato Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer